1 / 8

Objective

Do Changes of 6-minute Walk Distance Predict Clinical Events in Patients with Pulmonary Arterial Hypertension? A Meta-analysis Of 22 Randomized Trials.

jmoultrie
Télécharger la présentation

Objective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Do Changes of 6-minute Walk Distance Predict Clinical Events in Patients with Pulmonary Arterial Hypertension?A Meta-analysis Of 22 Randomized Trials Gianluigi Savarese, MD, Stefania Paolillo, MD, Pierluigi Costanzo, MD, Carmen D’Amore, MD, Milena Cecere, MD, Teresa Losco, MD, Francesca Musella, MD, Paola Gargiulo, MD, Caterina Marciano, MD, Pasquale Perrone-Filardi, MD, PhD

  2. Objective • To verify whether improvement in 6-minute walk distance (6MWD) is associated with clinical outcome in pulmonary arterial hypertension (PAH). J Am Coll Cardiol 2012;60:1193-202

  3. Background • 6MWD is used as end-point to assess the benefit of therapies in PAH. • However, whether changes in 6MWD correlate with clinical outcome is unknown. J Am Coll Cardiol 2012;60:1193-202

  4. Methods • Randomized trials in PAH patients assessing 6MWD and reporting clinical end- points were included in a meta-analysis. • Meta-analysis was performed to assess the influence of treatment on outcomes. • Meta-regression analysis was performed to test the relationship between 6MWD changes and outcomes. J Am Coll Cardiol 2012;60:1193-202

  5. Results • 22 trials enrolling 3,112 participants were included. • Active treatments led to significant reduction of • all-cause death • (odds ratio [OR]:0.429, 95% confidence interval [CI]:0.277 to 0.664, p<0.01), • hospitalization for PAH and/or lung or heart-lung transplantation • (OR:0.442, CI: 0.309 to 0.632, p<0.01), • initiation of PAH rescue therapy • (OR:0.555, CI:0.347 to 0.889, p=0.01) and • composite outcome • (OR:0.400, CI:0.313 to 0.510, p<0.01). • No relationship between 6MWD changes and outcomes was detected. J Am Coll Cardiol 2012;60:1193-202

  6. OR estimate of composite outcome in active treatment groups compared with control groups J Am Coll Cardiol 2012;60:1193-202

  7. Meta-regression between Δ6MWD and composite outcome (A), all-cause death (B), hospitalization for PAH and/or lung or heart-lung transplantation (C) and initiation of PAH rescue therapy (D). J Am Coll Cardiol 2012;60:1193-202

  8. Conclusion • In patients with PAH, improvement in 6MWD does not reflect reduction in clinical outcomes. J Am Coll Cardiol 2012;60:1193-202

More Related